2016 American Transplant Congress
Initial Experience Treating Hepatitis C Positive Kidney Transplant Recipients with Non-Interferon-Containing Regimens: Successes and Challenges.
Weill Cornell Medical College, New York, NY.
Historically, treatment of hepatitis C virus (HCV) infection with interferon-based regimens after kidney transplantation has been associated with risk of rejection & graft loss. Direct…2016 American Transplant Congress
HCV, Acute Rejection, and the New Direct-Acting Antivirals in Deceased Donor Kidney Transplant Recipients.
The association between hepatitis C virus (HCV) seropositivity and acute rejection (AR) in kidney transplant donors and recipients is unclear, and may have changed with…2016 American Transplant Congress
Induction Immunosuppression and Post-Transplant Outcomes in Kidney Recipients with Hepatitis C Virus.
Kidney transplantation is a well-established treatment option for ESRD patients with Hepatitis C virus (HCV). However, the optimal induction regimen for this population is uncertain,…2016 American Transplant Congress
Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV).
Aurora St Luke's Medical Center, Milwaukee, WI.
Background: Current guidelines recommend newer therapies over previous interferon-based treatments. The creation of a specialty pharmacy program within our institution that provides managed care for…2016 American Transplant Congress
A Sustained Viral Response Achieved with Sofosbuvir/Ledipasvir May Increase the Incidence of Acute Cellular Rejection Post Liver Transplantation.
Transplant Surgery, New York University Langone Medical Center, New York, NY.
Acute cellular rejection following liver transplantation has decreased in incidence with the use of potent immunosuppressive agents, affecting less than 25 percent of liver transplantation…2016 American Transplant Congress
Quantitative Hepatitis C Virus (HCV) RNA in Plasma and Kidney Tissue in HCV Antibody Positive Donors.
Background: Currently HCV antibody positive deceased donors renal allografts are not considered for transplantation in HCV negative recipients. With recent development of anti-HCV therapy, utilization…2015 American Transplant Congress
Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results from the HCV-TARGET Multicenter Prospective Observational Study
The safety and efficacy of direct-acting antivirals (DAA) for HCV post-LT remain unknown. METHODS: We describe the safety and efficacy of all oral DAA-therapy for…2015 American Transplant Congress
Sofosbuvir Therapy in Early and Late Post Liver Transplant Setting: A Single Center Experience
Background: Hepatitis C (HCV) treatment has entered a new phase of excitement with new oral therapies. Here we describe our experience of sofosbuvir (SOF) based…2015 American Transplant Congress
Changes in Utilization, Discard, and Outcomes Associated With Hepatitis C (+) Donor Livers in the Era of Direct Acting Anti-Retroviral Therapy
Johns Hopkins University, Baltimore, MD.
While 45% of liver candidates are hepatitis C (HCV) (+) and might benefit from an HCV (+) donor liver, only 7.1% receive one, and HCV…2015 American Transplant Congress
Pretransplant Hepatitis B Viral Infection Increased Risk of Death After Kidney Transplantation
Clinical outcomes have not been well evaluated in kidney transplant recipients (KTRs) with hepatitis B virus (HBV). Here, we aimed to investigate the recent posttransplant…
American Transplant Congress abstracts